Carisma Therapeutics (CARM) Competitors $0.43 -0.02 (-5.28%) As of 10:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CARM vs. EVGN, ADAP, PYRGF, VRCA, CNTB, STRO, IKNA, ANRO, CLSD, and ASRTShould you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include Evogene (EVGN), Adaptimmune Therapeutics (ADAP), PyroGenesis Canada (PYRGF), Verrica Pharmaceuticals (VRCA), Connect Biopharma (CNTB), Sutro Biopharma (STRO), Ikena Oncology (IKNA), Alto Neuroscience (ANRO), Clearside Biomedical (CLSD), and Assertio (ASRT). Carisma Therapeutics vs. Its Competitors Evogene Adaptimmune Therapeutics PyroGenesis Canada Verrica Pharmaceuticals Connect Biopharma Sutro Biopharma Ikena Oncology Alto Neuroscience Clearside Biomedical Assertio Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends. Which has more risk & volatility, CARM or EVGN? Carisma Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Comparatively, Evogene has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Is CARM or EVGN more profitable? Evogene has a net margin of -224.82% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-254.28% N/A -137.38% Evogene -224.82%-102.40%-39.19% Do analysts rate CARM or EVGN? Carisma Therapeutics currently has a consensus price target of $1.93, indicating a potential upside of 350.82%. Evogene has a consensus price target of $3.50, indicating a potential upside of 180.00%. Given Carisma Therapeutics' higher probable upside, equities research analysts plainly believe Carisma Therapeutics is more favorable than Evogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.43Evogene 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in CARM or EVGN? 44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 7.4% of Evogene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer CARM or EVGN? In the previous week, Carisma Therapeutics and Carisma Therapeutics both had 1 articles in the media. Carisma Therapeutics' average media sentiment score of 1.89 beat Evogene's score of 0.73 indicating that Carisma Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Carisma Therapeutics Very Positive Evogene Positive Which has higher earnings and valuation, CARM or EVGN? Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.91-$60.48M-$1.56-0.27Evogene$6.77M0.99-$16.49M-$2.69-0.46 SummaryCarisma Therapeutics beats Evogene on 9 of the 16 factors compared between the two stocks. Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CARM vs. The Competition Export to ExcelMetricCarisma TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.84M$2.43B$5.55B$9.25BDividend YieldN/A1.70%5.01%4.01%P/E Ratio-0.279.1828.4219.56Price / Sales0.91463.47375.4780.11Price / CashN/A22.3424.7327.56Price / Book-0.644.678.235.58Net Income-$60.48M$30.99M$3.21B$254.82M7 Day Performance6.22%2.67%3.36%1.97%1 Month Performance-5.45%22.76%9.36%11.72%1 Year Performance-66.11%-4.21%29.39%16.38% Carisma Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CARMCarisma Therapeutics3.0367 of 5 stars$0.43-5.3%$1.93+350.8%-62.4%$17.84M$19.63M-0.2720Positive NewsEVGNEvogene2.6883 of 5 stars$1.32-1.5%$3.50+165.2%-80.3%$7.19M$8.51M-0.49140ADAPAdaptimmune Therapeutics1.8105 of 5 stars$0.24-3.6%$1.35+460.6%-78.0%$66.26M$178.03M-0.89490PYRGFPyroGenesis Canada0.0932 of 5 stars$0.35+4.0%N/A-55.4%$66.16M$9.14M-5.9190Gap DownVRCAVerrica Pharmaceuticals4.5002 of 5 stars$0.83+17.4%$8.00+863.9%-90.4%$65.36M$7.57M-0.6940Gap UpCNTBConnect Biopharma3.1216 of 5 stars$1.14-2.5%$7.00+514.0%+12.8%$64.97M$26.03M0.00110STROSutro Biopharma4.2965 of 5 stars$0.74-2.9%$6.11+725.4%-81.6%$64.46M$62.04M-0.25240IKNAIkena Oncology2.7901 of 5 stars$1.35+1.5%$3.00+122.2%-19.9%$64.18M$9.16M-1.5770Gap UpANROAlto Neuroscience2.1611 of 5 stars$2.30-2.1%$8.50+269.6%-80.6%$63.62MN/A-0.98N/ACLSDClearside Biomedical2.0233 of 5 stars$0.82+0.3%$4.75+482.8%-33.7%$63.12M$1.66M-1.9930Positive NewsASRTAssertio1.8649 of 5 stars$0.66+0.5%$2.75+319.0%-58.7%$62.54M$124.96M-2.0520 Related Companies and Tools Related Companies Evogene Alternatives Adaptimmune Therapeutics Alternatives PyroGenesis Canada Alternatives Verrica Pharmaceuticals Alternatives Connect Biopharma Alternatives Sutro Biopharma Alternatives Ikena Oncology Alternatives Alto Neuroscience Alternatives Clearside Biomedical Alternatives Assertio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CARM) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CARM Stock Alerts